Key result
Lower circulating levels of IGFBP-1 were associated with increased odds of macrovascular disease in type 2 diabetes (OR 0.57; 95% CI 0.40-0.83; P=0.001).
Population
160 extensively characterized type 2 diabetic subjects
Design
Cohort
Follow-up
12 months
Authors
Loading...
Phosphorylation of IGFBP-1 may alter IGF-I bioavailability in diabetes; leaves open its vascular role in CVD.
Cohort (n=160)
Odds Ratio: 0.57 (95% CI 0.4–0.83)
p-value: p=0.001
Low circulating levels of highly phosphorylated IGFBP-1 are closely associated with macrovascular disease and hypertension in type 2 diabetes, suggesting a potential protective role against cardiovascular disease.
Heald et al. (2002) conducted a cohort in Type 2 diabetes (n=160). IGFBP-1 concentration vs. Higher IGFBP-1 concentration was evaluated on Presence of macrovascular disease (OR 0.57, 95% CI 0.40-0.83, p=0.001). Lower circulating levels of IGFBP-1 were associated with increased odds of macrovascular disease in type 2 diabetes (OR 0.57; 95% CI 0.40-0.83; P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: